Buoyed by renewed clamor for infectious disease R&D, Affinivax nabs huge $226M funding round badams Fri, 01/08/2021 - 07:17.: After getting off a meaty $120 million round in April, the height of the first wave of COVID-19 infections in the West, Affinivax is a clear indicator that infectious disease and vaccine work is here to stay. Nearly doubling that already impressive B round, the Cambridge, Massachusetts-based biotech has nabbed $226 million, with goals of unseating Pfizer’s Prevnar franchise as well as pushing a set of vaccines for hospital-associated infections into the clinic.